GCG and metabolic disease: The GLP-1 discovery and development of its agonists have revolutionized biomedical research focusing on metabolic disorders, such as obesity, T2DM, atherosclerosis and cardiovascular diseases (CVDs) and pharmaceutical industrial revenue.